• ALT/AST > 5 times the upper limit of normal. • Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) • Pregnancy or breast feeding. • Anticipated transfer to another hospital w hich is not a study site w ithin 72 hours. • Allergy to any study medication • Shortness of breath in resting position • Known prolonged QT syndrome • Use of concomitant medications that prolong the QT/QTc interval • Participant with other viral pneumonia • Participants with allergies to artemisinin containing products • History of allergic reactions to any investigational medical product ingredient

• ALT/AST > 5 times the upper limit of normal. • Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) • Pregnancy or breast feeding. • Anticipated transfer to another hospital w hich is not a study site w ithin 72 hours. • Allergy to any study medication • Shortness of breath in resting position • Known prolonged QT syndrome • Use of concomitant medications that prolong the QT/QTc interval • Participant with other viral pneumonia • Participants with allergies to artemisinin containing products • History of allergic reactions to any investigational medical product ingredient